Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Publikationen
Suchbegriffe: METASTATIC COLORECTAL CANCER, . Treffer: 20
2022
Gerger, A; Eisterer, W; Fuxius, S; Bastian, S; Koeberle, D; Welslau, M; Sanoyan, DA; Maas, C; Uhlig, J; Fenchel, K; Greil, R; VON, DER, Heyde, E; Agocs, GR; Weide, R; Schwager, M; Reichenbach, F; Modest, DP; Fritsch, R
Retrospective Analysis of Treatment Pathways in Patients With BRAFV600E-mutant Metastatic Colorectal Carcinoma - MORSECRC.
Anticancer Res. 2022; 42(10):4773-4785
Doi: 10.21873/anticanres.15982
Web of Science
PubMed
FullText
FullText_MUG
2021
Scheipner, L; Smolle, MA; Barth, D; Posch, F; Stotz, M; Pichler, M; StÖger, H; Gerger, A; Riedl, JM
The AST/ALT Ratio Is an Independent Prognostic Marker for Disease-free Survival in Stage II and III Colorectal Carcinoma.
Anticancer Res. 2021; 41(1):429-436
Doi: 10.21873/anticanres.14792
Web of Science
PubMed
FullText
FullText_MUG
Unseld, M; Belic, J; Pierer, K; Zhou, Q; Moser, T; Bauer, R; Piringer, G; Gerger, A; Siebenhüner, A; Speicher, M; Heitzer, E; Prager, GW
A higher ctDNA fraction decreases survival in regorafenib-treated metastatic colorectal cancer patients. Results from the regorafenib's liquid biopsy translational biomarker phase II pilot study.
Int J Cancer. 2021; 148(6):1452-1461
Doi: 10.1002/ijc.33303
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2020
Bianconi, D; Herac, M; Posch, F; Schmeidl, M; Unseld, M; Kieler, M; Brettner, R; Mullauer, L; Riedl, J; Gerger, A; Scheithauer, W; Prager, G
Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC.
THER ADV MED ONCOL. 2020; 12: 1758835920928635
Doi: 10.1177/1758835920928635
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Moik, F; Posch, F; Grilz, E; Scheithauer, W; Pabinger, I; Prager, G; Ay, C
Haemostatic biomarkers for prognosis and prediction of therapy response in patients with metastatic colorectal cancer.
Thromb Res. 2020; 187:9-17
Doi: 10.1016/j.thromres.2020.01.002
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Scherr, AL; Mock, A; Gdynia, G; Schmitt, N; Heilig, CE; Korell, F; Rhadakrishnan, P; Hoffmeister, P; Metzeler, KH; Schulze-Osthoff, K; Illert, AL; Boerries, M; Trojan, J; Waidmann, O; Falkenhorst, J; Siveke, J; Jost, PJ; Bitzer, M; Malek, NP; Vecchione, L; Jelas, I; Brors, B; Glimm, H; Stenzinger, A; Grekova, SP; Gehrig, T; Schulze-Bergkamen, H; Jäger, D; Schirmacher, P; Heikenwalder, M; Goeppert, B; Schneider, M; Fröhling, S; Köhler, BC
Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancer.
Cell Death Dis. 2020; 11(10):875
Doi: 10.1038/s41419-020-03092-7
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2017
Riedl, JM; Posch, F; Bezan, A; Szkandera, J; Smolle, MA; Winder, T; Rossmann, CH; Schaberl-Moser, R; Pichler, M; Stotz, M; Stöger, H; Gerger, A
Patterns of venous thromboembolism risk in patients with localized colorectal cancer undergoing adjuvant chemotherapy or active surveillance: an observational cohort study.
BMC Cancer. 2017; 17(1):415-415
Doi: 10.1186/s12885-017-3392-4
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Riedl, JM; Posch, F; Moik, F; Bezan, A; Szkandera, J; Smolle, MA; Kasparek, AK; Pichler, M; Stöger, H; Stotz, M; Gerger, A
Inflammatory biomarkers in metastatic colorectal cancer: prognostic and predictive role beyond the first line setting.
Oncotarget. 2017; 8(56):96048-96061
Doi: 10.18632/oncotarget.21647
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2016
Bonin, S; Donada, M; Bussolati, G; Nardon, E; Annaratone, L; Pichler, M; Chiaravalli, AM; Capella, C; Hoefler, G; Stanta, G
A synonymous EGFR polymorphism predicting responsiveness to anti-EGFR therapy in metastatic colorectal cancer patients.
Tumour Biol. 2016; 37(6):7295-7303
Doi: 10.1007/s13277-015-4543-3
Web of Science
PubMed
FullText
FullText_MUG
Bradatsch, A; Kornprat, P; Bacher, H; Cerwenka, H; Haybaeck, J; Mischinger, HJ
The Value of Lymph Node Dissection in the Surgery of Colorectal Cancer Liver Metastases.
Anticancer Res. 2016; 36(6):2993-2997
Web of Science
PubMed
2015
Kaczirek, K; Ciuleanu, TE; Vrbanec, D; Marton, E; Messinger, D; Liegl-Atzwanger, B; Wrba, F; Knittelfelder, R; Lindner, E; Zielinski, CC; Streubel, B; Brodowicz, T
FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
Clin Colorectal Cancer. 2015; 14(2):91-98
Doi: 10.1016/j.clcc.2014.12.003
Web of Science
PubMed
FullText
FullText_MUG
2014
Mohan, S; Heitzer, E; Ulz, P; Lafer, I; Lax, S; Auer, M; Pichler, M; Gerger, A; Eisner, F; Hoefler, G; Bauernhofer, T; Geigl, JB; Speicher, MR
Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing.
PLoS Genet. 2014; 10(3):e1004271-e1004271
Doi: 10.1371/journal.pgen.1004271
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2013
Dijkstra, JR; Heideman, DA; Meijer, GA; Boers, JE; 't Hart, NA; Diebold, J; Hirschmann, A; Hoefler, G; Winter, G; Miltenberger-Miltenyi, G; Pereira, SV; Richman, SD; Quirke, P; Rouleau, EL; Guinebretiere, JM; Tejpar, S; Biesmans, B; van Krieken, JH
KRAS mutation analysis on low percentage of colon cancer cells: the importance of quality assurance.
Virchows Arch. 2013; 462(1):39-46
Doi: 10.1007/s00428-012-1356-2
Web of Science
PubMed
FullText
FullText_MUG
2011
D'Angelica, M; Kornprat, P; Gonen, M; DeMatteo, RP; Fong, Y; Blumgart, LH; Jarnagin, WR
Effect on outcome of recurrence patterns after hepatectomy for colorectal metastases.
Ann Surg Oncol. 2011; 18(4):1096-1103
Doi: 10.1245/s10434-010-1409-1
Web of Science
PubMed
FullText
FullText_MUG
2010
Kriegshäuser, G; Auner, V; Zeillinger, R
New and potential clinical applications of KRAS as a cancer biomarker.
Expert Opin Med Diagn. 2010; 4(5):383-395
Doi: 10.1517/17530059.2010.510512
PubMed
FullText
FullText_MUG
Zhang, W; Azuma, M; Lurje, G; Gordon, MA; Yang, D; Pohl, A; Ning, Y; Bohanes, P; Gerger, A; Winder, T; Hollywood, E; Danenberg, KD; Saltz, L; Lenz, HJ
Molecular Predictors of Combination Targeted Therapies (Cetuximab, Bevacizumab) in Irinotecan-Refractory Colorectal Cancer (BOND-2 Study).
Anticancer Res. 2010; 30(10):4209-4217
Web of Science
PubMed
2009
Ausch, C; Buxhofer-Ausch, V; Oberkanins, C; Holzer, B; Minai-Pour, M; Jahn, S; Dandachi, N; Zeillinger, R; Kriegshäuser, G
Sensitive detection of KRAS mutations in archived formalin-fixed paraffin-embedded tissue using mutant-enriched PCR and reverse-hybridization.
J Mol Diagn. 2009; 11(6):508-513
Doi: 10.2353/jmoldx.2009.090022
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2005
Dandachi, N; Balic, M; Stanzer, S; Halm, M; Resel, M; Hinterleitner, TA; Samonigg, H; Bauernhofer, T
Critical evaluation of real-time reverse transcriptase-polymerase chain reaction for the quantitative detection of cytokeratin 20 mRNA in colorectal cancer patients.
J Mol Diagn. 2005; 7(5):631-637
Doi: 10.1016/S1525-1578(10)60597-1
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
1999
Hausmaninger, H; Moser, R; Samonigg, H; Mlineritsch, B; Schmidt, H; Pecherstorfer, M; Fridrik, M; Kopf, C; Nitsche, D; Kaider, A; Ludwig, H
Biochemical modulation of 5-fluorouracil by leucovorin with or without interferon-alpha-2c in patients with advanced colorectal cancer: final results of a randomised phase III study.
Eur J Cancer. 1999; 35(3):380-385
Doi: 10.1016%2FS0959-8049%2898%2900397-9
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
Samonigg, H; Wilders-Truschnig, M; Kuss, I; Plot, R; Stöger, H; Schmid, M; Bauernhofer, T; Tiran, A; Pieber, T; Havelec, L; Loibner, H
A double-blind randomized-phase II trial comparing immunization with antiidiotype goat antibody vaccine SCV 106 versus unspecific goat antibodies in patients with metastatic colorectal cancer.
J Immunother. 1999; 22(6):481-488
Doi: 10.1097/00002371-199911000-00002
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar